# Saltikva for Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct04589234/  
OnCo record `nct04589234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine and Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Salspera LLC, active and no longer recruiting.

## Summary

Saltikva for Metastatic Pancreatic Cancer is a phase 2 interventional study registered as NCT04589234 by Salspera LLC, with 60 participants enrolled, started 2020-10-20 and due to reach its primary completion in 2030-12-31. Interventions recorded: Salmonella-IL2, FOLFIRINOX Alone (Historical Controls) and Gemcitabine/Abraxane Alone (Historical Controls).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04589234
- Phase: 2
- Setting: A Phase 2 Study of Saltikva (Attenuated Salmonella Typhimurium Containing the Human Gene for Interleukin-2) in Patients With Metastatic Pancreatic Cancer
- Sponsor: Salspera LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04589234: https://clinicaltrials.gov/study/NCT04589234

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct04589234.json